Carcinoma, Non-Small-Cell Lung: all 6,641 studies
Page 11 of 67. Open to participants first (1,665), then studies with results posted, then the rest; newest registration first within each.
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyRecruitingNCT06362369Phase 1/2
- A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC PatientsRecruitingNCT06361927Phase 2
- Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)RecruitingNCT06361784
- Real World Study of Lolatinib for Advanced ALK+ NSCLC PatientsRecruitingNCT06361589
- Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) ScanRecruitingNCT06358222
- Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung CancerRecruitingNCT06357598Phase 4
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsRecruitingNCT06357533Phase 3
- A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to ImmunotherapyNot yet recruitingNCT06356675Phase 4
- Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RWRecruitingNCT06355609Phase 2
- An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain MetastasisRecruitingNCT06352502
- To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung CancerRecruitingNCT06352008Phase 2
- Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06350097Phase 3
- Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic PlatformRecruitingNCT06349642
- Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLCRecruitingNCT06348927Phase 2
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Phase 3
- Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerRecruitingNCT06343402Phase 1
- Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKIRecruitingNCT06343064Phase 1/2
- To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06341660Phase 2
- Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung CancerRecruitingNCT06341530Phase 2
- Volatolomic and Proteomic Profile for Early Diagnosis of Lung CancerRecruitingNCT06341387
- Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor FailureNot yet recruitingNCT06336954Phase 2
- A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC PatientsNot yet recruitingNCT06335355Phase 2/3
- Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment FailureRecruitingNCT06334757Phase 2
- Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLCRecruitingNCT06332755Phase 1
- A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung CancerRecruitingNCT06331650Phase 2
- Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and ResectionRecruitingNCT06331455Phase 2
- Anesthesia and Non-small Cell Lung Cancer RecurrenceRecruitingNCT06330038Phase 4
- High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain MetastasesNot yet recruitingNCT06319950Phase 2
- Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerNot yet recruitingNCT06319313Phase 2/3
- Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant ImmunotherapyRecruitingNCT06317558
- Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion.RecruitingNCT06317324
- Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisRecruitingNCT06315010Phase 2
- Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line ImmunotherapyRecruitingNCT06313541Phase 2
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingNCT06312137Phase 3
- Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly PatientsRecruitingNCT06311981Phase 2
- Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 InhibitorRecruitingNCT06310915
- A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLCRecruitingNCT06306456Phase 1/2
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsRecruitingNCT06305962Early Phase 1
- Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)RecruitingNCT06305715Phase 2
- FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCRecruitingNCT06303505Phase 1/2
- D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Phase 3
- Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene MutationsNot yet recruitingNCT06299371Phase 2
- Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.RecruitingNCT06296745Phase 2
- Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scanEnrolling by invitationNCT06293833Not applicable
- The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung CancerRecruitingNCT06287320
- A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.RecruitingNCT06284317Phase 3
- Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory TrialNot yet recruitingNCT06282536Phase 2
- Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.Enrolling by invitationNCT06281964Phase 3
- Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin AdministrationRecruitingNCT06281860Phase 1
- Recombinant Human Endostatin Combined With Envafolimab and Synchronal RadiochemotherapyNot yet recruitingNCT06279754Phase 2
- Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKIRecruitingNCT06277674Phase 2
- DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)RecruitingNCT06276283Phase 2
- Repositioning Immunotherapy in VetArans With Lung CancerRecruitingNCT06275360Phase 2
- BostonGene and Exigent Genomic INsight StudyRecruitingNCT06272864
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsRecruitingNCT06270706Phase 1
- Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive ExpressionRecruitingNCT06269211Phase 2
- A Study of KK2269 in Adult Participants With Solid TumorsRecruitingNCT06266299Phase 1
- Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramRecruitingNCT06265285Phase 2
- Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the ThoraxRecruitingNCT06262321Phase 2
- Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLCEnrolling by invitationNCT06260553Phase 2
- A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCNot yet recruitingNCT06254599Phase 3
- A Phase 1/1b Study of IAM1363 in HER2 CancersRecruitingNCT06253871Phase 1
- Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung CancerRecruitingNCT06250829
- Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain MetastasesEnrolling by invitationNCT06250777Phase 2
- Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06249282Phase 1
- Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesRecruitingNCT06248606Phase 2
- Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 InsertionRecruitingNCT06247826Not applicable
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsRecruitingNCT06244771Phase 1/2
- A Study of MGC026 in Participants With Advanced Solid TumorsRecruitingNCT06242470Phase 1
- Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLCRecruitingNCT06241807Phase 2
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsRecruitingNCT06239194Phase 1/2
- Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.RecruitingNCT06238882Not applicable
- Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)RecruitingNCT06234579
- An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscoreRecruitingNCT06232265
- Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)RecruitingNCT06231680Phase 2
- Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6RecruitingNCT06228482Phase 1
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsRecruitingNCT06228326Phase 1/2
- Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.RecruitingNCT06227728
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung CancerRecruitingNCT06225804Phase 1
- Gilteritinib for the Treatment of ALK NSCLCRecruitingNCT06225427Phase 1
- Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CTRecruitingNCT06222489Phase 2
- Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse EffectsRecruitingNCT06221800
- Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)RecruitingNCT06221670Phase 2
- Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung CancerNot yet recruitingNCT06221462Phase 2
- HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLCNot yet recruitingNCT06218940Phase 1
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsRecruitingNCT06218914Phase 1
- LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCRecruitingNCT06216301Phase 3
- A Study of HLX42 in Advanced/Metastatic Solid TumorsRecruitingNCT06210815Phase 1
- SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06208033Early Phase 1
- Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung CancerRecruitingNCT06207292Not applicable
- Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung CancerRecruitingNCT06205927Phase 2
- Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)Not yet recruitingNCT06198907Phase 2
- MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLCRecruitingNCT06198868
- PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLCRecruitingNCT06195527
- Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/IIRecruitingNCT06195189Phase 1/2
- To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyRecruitingNCT06192849Phase 2
- The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical StudyRecruitingNCT06188650Not applicable
- RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNot yet recruitingNCT06185400Phase 2
- Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line ImmunotherapyNot yet recruitingNCT06182800Phase 2
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationRecruitingNCT06179160Phase 1